A brave new world for supplementary protection certificates?
01 August 2012
Life Sciences Intellectual Property Review 2012
Authors: Mike Snodin and Michael Pears
This article appeared in the 2012 edition of Life Sciences Intellectual Property Review. It discusses the opinion of Advocate-General Verica Trstenjak in the case of Neurim Pharmaceuticals (C-130/11). Whilst agreeing that it would be very harsh upon Neurim if they were not awarded and SPC, Mike and Michael highlight possible undesired side-effects in implementing the particular "fix" proposed by the Advocate-General that would award an SPC to Neurim.